Clinical Trial Update: Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating adjuvant paclitaxel and trastuzumab for node-negative HER2-positive breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Herceptin (trastuzumab) (trastuzumab)
• Taxol (paclitaxel) (paclitaxel)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Breast Cancer, Carcinoma of the Breast | Phase 2 | Status: COMPLETED | Results posted: 2023-03-27